ENTX NASDAQ
Entera Bio Ltd.
1W: +4.0%
1M: -2.0%
3M: +67.2%
YTD: +61.6%
1Y: +54.6%
3Y: +297.8%
5Y: -40.5%
$2.86
-0.03 (-1.04%)
Weekly Expected Move ±6.8%
$2
$3
$3
$3
$3
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships6
As Filer
counterparties named
1
As Counterparty
mentioned by others
1
Rel. Types
2022-05-16
Earliest Filing
2026-02-04
Latest Filing
partner: 6
Counterparties (Filed by ENTX)
6 relationshipsCompanies named in ENTX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| OPKO Biologics Ltd. | — | partner | Israeli biopharmaceutical company entering collaboration and license agreement | 2026-02-04 | View |
| OPKO Health, Inc. | OPK | partner | Delaware corporation entering collaboration and license agreement | 2026-02-04 | View |
| Entera Bio Ltd. | ENTX | partner | Israeli biopharmaceutical company entering collaboration and license agreement | 2026-02-04 | View |
| OPKO BIOLOGICS LTD. | — | partner | Collaborator in oral dual agonist GLP-1/glucagon peptide development | 2025-03-17 | View |
| OPKO HEALTH, INC. | OPK | partner | Collaborator and potential commercialization partner for oral products | 2025-03-17 | View |
| ENTERA BIO LTD. | ENTX | partner | Collaborator providing N-Tab™ technology platform for oral delivery | 2025-03-17 | View |
Mentioned As Counterparty
1 mentionsOther companies that named ENTX in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-18 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-07 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-07-28 | Material Agreement; Unregistered Equity Sales; Officer/Director Change; Exhibits | Agreement | View |
| 2026-07-16 | Officer/Director Change; Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-05-08 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-04-03 | Material Agreement; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-03-27 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-03-04 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-02-09 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2026-02-04 | Entry into Material Definitive Agreement; Departure/Election of Directors; Appointment of Officers; | Agreement | View |
| 2025-11-14 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-08-08 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-07-28 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-07-18 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-09 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-03-28 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-03-17 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-01-10 | Financial Statements and Exhibits | View | |
| 2024-12-20 | Submission of Matters to a Vote of Security Holders | View | |
| 2024-11-08 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR